Latest Conference Content

Mark Malesker, PharmD, discusses the clinical evidence, drug interaction risks, and formulary challenges surrounding cannabinoid use for sleep disorders.

In a VESALIUS-CV subgroup analysis, evolocumab cut MACE by 29% in high-risk diabetes, reinforcing intensive LDL lowering for CV risk reduction.

After decades of neglect, malnutrition-related diabetes, or type 5, is finally getting the research, recognition, and clinical framework it demands.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

The lead investigator for SUCCESSOR-2 discusses the potency of a potential successor to pomalidomide in treatment of multiple myeloma, with survival outcomes that rival CAR T-cell therapy.

EHA 2026 late-breaking data featured phase 3 trials in CLL, AML, multiple myeloma, and myelofibrosis, plus early CAR T data in B-cell lymphoma and ITP.

Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

Replacing chemotherapy with blinatumomab improved event-free survival and reduced toxicity in high-risk pediatric ALL, data show.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.

Experts sparred over the feasibility and appropriateness of using minimal residual disease (MRD) to determine the duration of first-line CLL treatment.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

The conference, set to take place in Baltimore, Maryland, will feature 4 days of sessions focusing on sleep medicine and how it affects overall health.

Final results of the CLL14 study reveal the efficacy of 1-year venetoclax-obinutuzumab therapy for chronic lymphocytic leukemia.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Longer patient survival times require a shift toward earlier surrogate end points, with measurable residual disease (MRD) providing robust evidence of its utility for accelerating access to myeloma treatment.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

SC isatuximab via OBI earned EU approval in multiple myeloma, showing less than 1% IRR rates, strong reliability, and potential for at-home use.

A thriving gut microbiome is associated with better clinical outcomes after CAR T-cell therapy for lymphoma and myeloma.

Shannon L. Maude, MD, PhD, highlighted promising long-term disease-free survival and MRD negativity with tisagenleucel in high-risk pediatric ALL.

Ziftomenib plus intensive chemotherapy produced high response and MRD negativity rates with manageable safety in newly diagnosed AML.

Long-term LUNA3 data showed rilzabrutinib delivered durable platelet responses, reduced bleeding and fatigue, and maintained safety in ITP.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

Re-engagement strategies for hepatitis B show promise in the US, but data gaps and structural barriers are slowing progress toward WHO elimination targets.

At ADA 2026, experts explored how GLP-1 receptor agonists are reshaping treatment for obesity, osteoarthritis, nutrition, and muscle preservation.